Screener
Mirum Pharmaceuticals, Inc. MIRM Q2 2026 earnings
Reported August 5, 2026 · After market close
Revenue$176.2MBeat by $9.9M
EPS-$1.06Miss by $0.32
Revenue estimate$166.3M
EPS estimate-$0.74
“Mirum delivered another strong quarter, with continued commercial momentum supporting an increase to our full-year net product sales guidance and launch readiness for the upcoming potential approval of zilurgisertib. The FDA's decision to grant volixibat Breakthrough Therapy and Orphan Drug Designations underscores the strength of the VISTAS efficacy data and the serious unmet need in PSC. VISTAS was designed with FDA input as a pivotal study and met its primary endpoint with highly significant results. However, at our recent pre-NDA meeting, the agency recommended conducting a Phase 3 study. We intend to hold further discussions with the FDA before a potential NDA submission in the first half of 2027 based on VISTAS.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$178.1M
EPS estimate-$0.53
Valuation & ratios
Segments
By product
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Mirum Pharmaceuticals, Inc. report Q2 2026 earnings?
- Mirum Pharmaceuticals, Inc. (MIRM) reported Q2 2026 earnings on August 5, 2026 after market close.
- What were Mirum Pharmaceuticals, Inc.'s Q2 2026 revenue and EPS?
- Mirum Pharmaceuticals, Inc. reported revenue of $176.2M and eps of $-1.06 for Q2 2026.
- Did Mirum Pharmaceuticals, Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $166.3M by $9.9M. EPS missed the consensus estimate of $-0.74 by $0.32.
- How did Mirum Pharmaceuticals, Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 37.9% from $127.8M a year earlier and eps declined 783.3% from $-0.12.
- Where can I find Mirum Pharmaceuticals, Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001759425-26-000044) and the 10-Q periodic report (0001759425-26-000045) directly on SEC EDGAR. The filing index links above go to sec.gov.
